NASDAQ:DCTH Delcath Systems Q2 2025 Earnings Report $11.41 +0.01 (+0.09%) Closing price 04:00 PM EasternExtended Trading$11.35 -0.06 (-0.53%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Delcath Systems EPS ResultsActual EPSN/AConsensus EPS $0.02Beat/MissN/AOne Year Ago EPSN/ADelcath Systems Revenue ResultsActual RevenueN/AExpected Revenue$22.84 millionBeat/MissN/AYoY Revenue GrowthN/ADelcath Systems Announcement DetailsQuarterQ2 2025Date8/6/2025TimeBefore Market OpensConference Call DateWednesday, August 6, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Delcath Systems Earnings HeadlinesDelcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 25 at 4:01 PM | businesswire.comDelcath Systems to Host Second Quarter 2025 Earnings CallJuly 23 at 4:01 PM | businesswire.com[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…July 25 at 2:00 AM | GoldCo Precious Metals (Ad)Loss-Making Delcath Systems, Inc. (NASDAQ:DCTH) Set To BreakevenJune 24, 2025 | uk.finance.yahoo.comDelcath Systems: Growing Fast, But Business Model Is FragileJune 12, 2025 | seekingalpha.comDelcath forecasts $94-98 million in 2025 revenue, plans Medicaid dealMay 23, 2025 | investing.comSee More Delcath Systems Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Delcath Systems? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Delcath Systems and other key companies, straight to your email. Email Address About Delcath SystemsDelcath Systems (NASDAQ:DCTH), an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.View Delcath Systems ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings?Why Freeport-McMoRan Stock May Hit a New High After Earnings BeatMicrosoft’s AI Bet Faces a Major Test This Earnings SeasonAmazon Stock Rally Hits New Highs: Buy Into Earnings?TSLA Earnings Week: Can Tesla Break Through $350?Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your Portfolio Upcoming Earnings Cadence Design Systems (7/28/2025)Enterprise Products Partners (7/28/2025)Welltower (7/28/2025)Waste Management (7/28/2025)AstraZeneca (7/29/2025)Booking (7/29/2025)Mondelez International (7/29/2025)PayPal (7/29/2025)Starbucks (7/29/2025)American Tower (7/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
